Pharmacokinetics of diflunisal in patients
- PMID: 2029803
- DOI: 10.2165/00003088-199120010-00006
Pharmacokinetics of diflunisal in patients
Abstract
There are few pharmacokinetic data available on the disposition of diflunisal in patients; this study, therefore, looked at the oral absorption, distribution and elimination of this drug. Ten pharmacokinetic profiles obtained from 8 patients showed a maximum plasma diflunisal concentration of 62.0 +/- 26.5 mg/L after 2.76 +/- 1.87 hours, and an area under the plasma concentration-time curve (AUC) of 678.3 +/- 362.3 mg/L.h. Significant intra- and intersubject variability was observed in this group of patients. Analysis of biliary secretion of diflunisal in 4 patients suggested a biliary elimination and subsequent enterohepatic circulation ranging between 2.4 and 15.1%. The AUC for diflunisal in synovial fluid collected from 66 patients was about 70% of that for plasma. In none of 28 patients studied could any trace of diflunisal be observed in cerebrospinal fluid, even though the sensitivity of the assay allowed detection of concentrations as low as 0.01 mg/L.
Similar articles
-
Biliary excretion of diflunisal conjugates in patients with T-tube drainage.Eur J Clin Pharmacol. 1988;34(4):423-6. doi: 10.1007/BF00542448. Eur J Clin Pharmacol. 1988. PMID: 3402529
-
High-performance liquid chromatographic analysis of diflunisal in plasma and urine: application to pharmacokinetic studies in two normal volunteers.J Pharm Sci. 1983 Dec;72(12):1403-5. doi: 10.1002/jps.2600721209. J Pharm Sci. 1983. PMID: 6663474
-
Buffering the stomach content enhances the absorption of diflunisal in man.Biopharm Drug Dispos. 1989 Jul-Aug;10(4):377-87. doi: 10.1002/bdd.2510100405. Biopharm Drug Dispos. 1989. PMID: 2547464 Clinical Trial.
-
Effects of blockage of urine and/or bile flow on diflunisal conjugation and disposition in rats.Xenobiotica. 1990 Aug;20(8):835-45. doi: 10.3109/00498259009046897. Xenobiotica. 1990. PMID: 2219966
-
Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.Clin Pharmacokinet. 1989 Sep;17(3):145-62. doi: 10.2165/00003088-198917030-00002. Clin Pharmacokinet. 1989. PMID: 2680211 Review.
Cited by
-
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.Elife. 2016 May 31;5:e11156. doi: 10.7554/eLife.11156. Elife. 2016. PMID: 27244239 Free PMC article.
-
The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.Drugs. 1994;47 Suppl 5:28-45; discussion 46-7. doi: 10.2165/00003495-199400475-00006. Drugs. 1994. PMID: 7525183 Review.
-
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.Mol Cell Proteomics. 2017 Oct;16(10):1864-1888. doi: 10.1074/mcp.M116.064451. Epub 2017 Aug 9. Mol Cell Proteomics. 2017. PMID: 28794006 Free PMC article.
-
Central mediators involved in the febrile response: effects of antipyretic drugs.Temperature (Austin). 2015 Oct 13;2(4):506-21. doi: 10.1080/23328940.2015.1102802. eCollection 2015 Oct-Dec. Temperature (Austin). 2015. PMID: 27227071 Free PMC article. Review.
-
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.J Med Chem. 2020 Aug 13;63(15):8314-8324. doi: 10.1021/acs.jmedchem.0c00546. Epub 2020 Jul 28. J Med Chem. 2020. PMID: 32658475 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources